Lens S, et al. - This retrospective multicentre trial inspected the risk factors associated with hepatitis B virus recurrence after liver transplantation in a large cohort of patients under different hepatitis B immunoglobulin regimens. During this study, the strategy of short-term hepatitis B immunoglobulin was compared to lifelong administration. Yielded results depicted that liver transplantation served as an effective treatment for hepatitis B virus-related liver disease. Since the introduction of combined prophylaxis, the rate of hepatitis B virus recurrence was discovered to be very low. Nonetheless, lifelong hepatitis B immunoglobulin administration did not appear to be required for the reduction of hepatitis B virus recurrence.